
Lyphe Group is the UK’s medical cannabis pioneer.
Our vertical operations span product manufacturing, clinical care, pharmacy dispensing and doctor education. Our direct-to-patient and technology-led approach has quickly established us as the market’s largest player, with a 30% share of all patients. We have also recently entered the Australian market, where we intend to replicate our model of success.
Lyphe Group milestones
Feb 2023
Lyphe Group secures growth capital to focus on core UK and Australian markets
Dec 2022
TMCC changes its name to Lyphe Clinic
Aug 2022
Lyphe Australia is launched
Dec 2021
Lyphe become product provider into Europe’s largest RWD registry, Project Twenty21
Jan 2021
Dispensary Green passes milestone of 20,000 units dispensed
Dec 2020
TMCC passes 1,500 unique patients
Nov 2020
NOIDECS medical cannabis range launches into market
Sep 2020
TMCC completes first 1,000 medical cannabis consultations
Aug 2020
Dispensary Green passes milestone of 5,000 units dispensed
May 2020
Close Series A round
Mar 2020
Full telemedicine activation for all The Medical Cannabis Clinics patients
Feb 2020
Astral Health coordinates Israel's first export into the UK
Jan 2020
Open 7 clinic locations across the UK
Dec 2019
CQC granted license for The Medical Cannabis Clinics to open
Oct 2019
Reporters join us on our trip to pick up medication in Holland in a world first
Oct 2019
Demerged from incubator ECH, established Lyphe Group
Jun 2018